Insights on KLDO
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 50.9% return, outperforming this stock by 100.9%
Highlights
Market Capitalization | 4.3K |
Book Value | $0.25 |
Earnings Per Share (EPS) | -2.16 |
Wall Street Target Price | 22.0 |
Profit Margin | 0.0% |
Operating Margin TTM | -3974.39% |
Return On Assets TTM | -99.93% |
Return On Equity TTM | -580.57% |
Revenue TTM | 1.1M |
Revenue Per Share TTM | 0.03 |
Quarterly Revenue Growth YOY | 102.49999999999999% |
Gross Profit TTM | -66.7M |
EBITDA | -85.2M |
Diluted Eps TTM | -2.16 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | 0.0 |
EPS Estimate Next Year | 0.0 |
EPS Estimate Current Quarter | 0.0 |
EPS Estimate Next Quarter | 0.0 |
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Moderna, Inc. | -2.26% | 35.27% | -21.9% | -39.25% | 318.83% |
 Regeneron Pharmaceuticals, Inc. | -5.59% | 12.81% | 13.84% | 81.04% | 166.5% |
 Novo Nordisk A/s | -0.32% | 31.91% | 50.92% | 247.21% | 431.9% |
 Vertex Pharmaceuticals Incorporated | -2.67% | 9.62% | 21.65% | 86.62% | 134.62% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Moderna, Inc. | 24.73 | NA | 0.0 | -7.22 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 25.9 | 25.9 | 1.46 | 45.02 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 47.09 | 47.09 | 2.4 | 3.33 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.81 | 28.81 | 0.53 | 16.76 | 0.23 | 0.13 | NA | 68.22 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Moderna, Inc. | Buy | $40.0B | 318.83% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $98.8B | 166.5% | 25.9 | 30.14% |
Novo Nordisk A/s | Buy | $558.9B | 431.9% | 47.09 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $103.4B | 134.62% | 28.81 | 36.68% |
